Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient
source: pixabay.com

Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient

Duchenne muscular dystrophy (DMD) is an inherited disease that weakens a child’s muscles and eventually spreads throughout the child’s body. DMD is caused by mutations in the gene that helps…

Continue Reading Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient

CureDuchenne’s Cares Dinner Session: Tampa, FL

  • Post author:
  • Post category:

CureDuchenne Cares Dinner Session March 16, 2024 Tampa, FL A NEIGHBORHOOD DINNER FOR CAREGIVERS AFFECTED BY DUCHENNE AND BECKER JOIN US FOR A CASUAL THREE-HOUR DINNER ON SATURDAY EVENING TO…

Continue Reading CureDuchenne’s Cares Dinner Session: Tampa, FL
PGN-EDO51 Granted Orphan Drug Designation for Duchenne Muscular Dystrophy (DMD)
source: shutterstock.com

PGN-EDO51 Granted Orphan Drug Designation for Duchenne Muscular Dystrophy (DMD)

Editor's Note: Chronic conditions and rare diseases don't discriminate, Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have…

Continue Reading PGN-EDO51 Granted Orphan Drug Designation for Duchenne Muscular Dystrophy (DMD)

CureDuchenne’s Cares Dinner Session: Charlotte, NC

  • Post author:
  • Post category:

CureDuchenne Cares Dinner Session February 24, 2024 Charlotte, NC A NEIGHBORHOOD DINNER FOR CAREGIVERS AFFECTED BY DUCHENNE AND BECKER JOIN US FOR A CASUAL THREE-HOUR DINNER ON SATURDAY EVENING TO…

Continue Reading CureDuchenne’s Cares Dinner Session: Charlotte, NC
Patricia Brown Joins CureDuchenne as Senior Director of Engagement to Advance Mission of Finding Duchenne Muscular Dystrophy Cure
rawpixel / Pixabay

Patricia Brown Joins CureDuchenne as Senior Director of Engagement to Advance Mission of Finding Duchenne Muscular Dystrophy Cure

For over 20 years, CureDuchenne, a Patient Worthy partner and global nonprofit, has moved steadfastly forward with a mission to find, and fund, a cure for individuals with Duchenne muscular…

Continue Reading Patricia Brown Joins CureDuchenne as Senior Director of Engagement to Advance Mission of Finding Duchenne Muscular Dystrophy Cure
Sarepta is Pushing to Expand Duchenne Muscular Dystrophy Drug Label Despite Missed Endpoints
source: shutterstock.com

Sarepta is Pushing to Expand Duchenne Muscular Dystrophy Drug Label Despite Missed Endpoints

Sarepta Therapeutics’ treatment Elevidys (delandistrogene moxeparvovec-rokl) received conditional approval from the FDA in June 2023. The designation implies that if the drug is used in accordance with its label, it…

Continue Reading Sarepta is Pushing to Expand Duchenne Muscular Dystrophy Drug Label Despite Missed Endpoints

SGT-003 Granted Orphan Drug Designation for Duchenne Muscular Dystrophy (DMD)

The research landscape for Duchenne muscular dystrophy (DMD) has been steadily increasing. Researchers are exploring more therapies, including gene therapies, that could transform the lives of those with this rare…

Continue Reading SGT-003 Granted Orphan Drug Designation for Duchenne Muscular Dystrophy (DMD)
Vamorolone Has Been FDA Approved to Treat Duchenne Muscular Dystrophy
Source: https://unsplash.com/photos/ZHys6xN7sUE

Vamorolone Has Been FDA Approved to Treat Duchenne Muscular Dystrophy

Vamorolone, now marketed as AGAMREE®, is termed a dissociative steroid therapy, as it has proven its potential to retain the muscle-strengthening and anti-inflammatory benefits of corticosteroids. On the other side…

Continue Reading Vamorolone Has Been FDA Approved to Treat Duchenne Muscular Dystrophy
Rare Community Profiles: Destroy Duchenne: How Elijah Stacy is Working to Improve the Lives of People with Duchenne Muscular Dystrophy
Photo courtesy of Elijah Stacey

Rare Community Profiles: Destroy Duchenne: How Elijah Stacy is Working to Improve the Lives of People with Duchenne Muscular Dystrophy

Rare Community Profiles     Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

Continue Reading Rare Community Profiles: Destroy Duchenne: How Elijah Stacy is Working to Improve the Lives of People with Duchenne Muscular Dystrophy

CureDuchenne Launches the CureDuchenne Caregiver Course to Support Caregivers of People with DMD

  Since its founding 20 years ago, CureDuchenne has been tirelessly working to find and fund a cure for Duchenne muscular dystrophy (DMD). They have done this through supporting families,…

Continue Reading CureDuchenne Launches the CureDuchenne Caregiver Course to Support Caregivers of People with DMD
A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
source: shutterstock.com

A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy

  It looked as if the fate of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy was pretty much sealed until an FDA official intervened. This information was provided by…

Continue Reading A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link
source: shutterstock.com

Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: A Partnership Between CureDuchenne and PicnicHealth Bolsters the Power of CureDuchenne Link
MP1032 Earns Orphan Drug Designation for DMD
Source: https://pixabay.com/en/sky-clouds-rays-sun-hope-sunbeam-1107952/

MP1032 Earns Orphan Drug Designation for DMD

As reported in Yahoo! Finance, the United States’ Food and Drug Administration (FDA) recently granted Orphan Drug designation to MP1032. This therapy, developed by clinical-stage biotech company MetrioPharm, is being…

Continue Reading MP1032 Earns Orphan Drug Designation for DMD
Rare Community Profiles: CureDuchenne Clinic in Greater Dallas Area Aims to Improve Treatment Accessibility and Care for Underserved Families with DMD and BMD
source: shutterstock.com

Rare Community Profiles: CureDuchenne Clinic in Greater Dallas Area Aims to Improve Treatment Accessibility and Care for Underserved Families with DMD and BMD

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: CureDuchenne Clinic in Greater Dallas Area Aims to Improve Treatment Accessibility and Care for Underserved Families with DMD and BMD
Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation
source: shutterstock.com

Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation

According to a story from PR Newswire, the biopharmaceutical company Avidity Biosciences, Inc., recently announced that its investigational therapy AOC 1044 has received the US Food and Drug Administration's Fast…

Continue Reading Experimental Duchenne Muscular Dystrophy Treatment Earns Fast Track Designation
MDA Clinical & Scientific Conference: Givinostat Improves Physical Function and Mobility in DMD
Source: https://pixabay.com/en/stairway-staircase-stairs-outdoors-828883/

MDA Clinical & Scientific Conference: Givinostat Improves Physical Function and Mobility in DMD

The Muscular Dystrophy Association (MDA) recently held its MDA Clinical & Scientific Conference in March 2023. During the conference, stakeholders in the community discussed research trends and clinical practices associated…

Continue Reading MDA Clinical & Scientific Conference: Givinostat Improves Physical Function and Mobility in DMD